Clinical Scorecard: Insights from Dermatologists and Allergists on the Management and Treatment of Chronic Urticaria in China
At a Glance
Category
Detail
Condition
Clinical topic addressed by the source article: Insights from Dermatologists and Allergists on the Management and Treatment of Chronic Urticaria in China
Key Mechanisms
Mechanisms or clinical associations described in the source article.
Target Population
Physicians in China who diagnose and treat CU, as represented in a survey of 265 respondents.
Care Setting
China’s nationally standardized, tiered hospital system, which influences referral routes, case complexity, and access to advanced diagnostic procedures and biologic therapies.
Key Highlights
Among 265 surveyed physicians, 19% reported that their patients had inadequately controlled CU.
Complete disease control was a priority for 93% of physicians, but they considered it achievable for only 59% of patients.
Physicians reported a mean diagnostic delay of 1.3 years and consultations with four specialists.
Physicians reported referrals to psychological support and sleep services for 25% and 23% of patients, respectively; sleep disturbance was reported in 44% and mental health burden was rated 7.1/10.
The study reported conservative treatment escalation and a disparity between physicians’ satisfaction with biologics and their utilization.
Guideline-Based Recommendations
Diagnosis
Management
The cited EAACI guidance recommends second-generation H1-antihistamines initially, with dose escalation up to four times the standard dose if response is inadequate.
The cited treatment sequence recommends omalizumab after inadequate response to H1-antihistamines, followed by ciclosporin if control remains insufficient.
The article states that the 2025 guideline update incorporated omalizumab as add-on treatment after H1-antihistamines and listed dupilumab and remibrutinib as second-line options.
The Chinese Society of Dermatology’s revised 2022 guidelines adopted a stepwise framework aligned with EAACI 2022 recommendations.
Monitoring & Follow-up
The study assessed physician-reported disease burden across life domains, including mental health and sleep, and treatment patterns and satisfaction. This is study scope, not a monitoring recommendation.
Risks
Patient & Prescribing Data
The physician survey covered care for patients with CSU, CIndU, or both. Separately, cited literature estimates that nearly 20–30% of adults with CSU also have CIndU.
Physicians reported inadequate control in 19% of patients and considered complete control achievable for 59%. The article reports conservative escalation and a gap between physician satisfaction with biologics and their utilization.
Clinical Best Practices
The cited guidelines describe stepwise treatment approaches, including second-generation H1-antihistamines and subsequent escalation as specified in the guideline_recommendations section.
The article reports that CU affects sleep, workplace productivity, and mental health; the study assessed these domains.
The study reports diagnostic delays, fragmented care pathways, and limited referrals to psychological and sleep services; present these as findings rather than recommendations.
